Vir Biotechnology Announces First Participant Dosed in New Phase 1 Trial Evaluating VIR-1388, an Investigational T Cell Vaccine for the Prevention of HIV
September 20, 2023 08:00 ET
|
Vir Biotechnology, Inc.
– Based on a novel human cytomegalovirus vector platform, VIR-1388 was designed with the goal of creating a novel HIV vaccine – – Phase 1 trial supported by the Bill & Melinda Gates Foundation,...